Recombinant Human Lactate Dehydrogenase A/LDHA Protein, CF

Catalog #: 9158-HA Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
9158-HA-010
9158-HA-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

All Lactate Dehydrogenase A/LDHA Proteins and Enzymes

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human Lactate Dehydrogenase A/LDHA Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to reduce pyruvate to lactate. The specific activity is >95,000 pmol/min/μg, as measured under the described conditions.

Source

E. coli-derived human Lactate Dehydrogenase A/LDHA protein
Ala2-Phe332, with N-terminal Met and 6-His tag

Accession #

P00338

N-terminal Sequence
Analysis

Met

Predicted Molecular Mass

38 kDa

SDS-PAGE

36 kDa, reducing conditions

Product Datasheets

9158-HA

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9158-HA

Formulation	Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

Materials

Assay Buffer: 25 mM Tris, 100 mM NaCl, pH 7.5
Recombinant Human Lactate Dehydrogenase A/LDHA (rhLDHA) (Catalog # 9158-HA)
beta -Nicotinamide adenine dinucleotide, reduced disodium salt hydrate ( beta -NADH) (Sigma, Catalog # N8129), 20 mM stock in 0.1 M Sodium Borate, pH 9.0
100 mM Sodium Pyruvate (Gibco, Catalog # 11360)
96-well Clear Plate (Catalog # DY990)
Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent

Dilute rhLDHA to 0.4 ng/µL in Assay Buffer.
Prepare a substrate mixture containing 1.6 mM beta -NADH and 4 mM sodium pyruvate in Assay Buffer.
In a plate load 50 µL of 0.4 ng/µL rhLDHA, and start the reaction by adding 50 µL of substrate mixture. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL of substrate mixture.
Read plate at 340 nm (absorbance) in kinetic mode for 5 minutes.
Calculate specific activity:

Specific Activity (pmol/min/µg) =	Adjusted V_max* (OD/min) x well volume (L) x 10¹² pmol/mol x (-1)
	ext. coeff (M^-1cm^-1) x path corr.* (cm) x amount of enzyme (µg)

     *Adjusted for Substrate Blank.
     **Using the extinction coefficient 6220 M^-1cm^-1_.
     ***Using the path correction 0.320 cm.
     Note: the output of many spectrophotometers is in mOD.

Per Well:

rhLDHA: 0.020 µg
beta -NADH: 0.8 mM
Sodium pyruvate: 2 mM

Reconstitution Calculator

Background: Lactate Dehydrogenase A/LDHA

A hallmark of most cancer cells is an altered metabolism involving a shift to aerobic glycolysis with lactate production coupled with a higher uptake of glucose as the main source of energy. Lactate dehydrogenase (LDH) is key to this shift by catalyzing the formation of lactate by reducing pyruvate with NADH, which also generates NAD(+) that is essential for the continuity of glycolysis (1). LDHA is a key enzyme that controls the production of lactate in the glycolysis pathway. It is therefore an important control point in the system of cellular energy release. It's up regulation is common in many malignant tumors. Inhibiting LDH activity has an anti-proliferative effect on cancer cells (2). It may reverse the resistance of tumor cells to conventional chemo- and radiotherapy. Recent research has renewed interest in LDH as an anticancer drug target (3).The protein is found predominantly in muscle tissue. Mutations in LDHA have been linked to exertional myoglobinuria (4).

References

Faloppi L. et al. (2016) Sci Rep. doi: 10.1038/srep24136.
Ghosh, M. et al. (2016) Chem. Commun. 52:2401.
Augoff, K. et al. (2015) Cancer Lett. 358:1.
Maekawa M. et al. (1990). Biochem. Biophys. Res. Commun. 168:677.

Entrez Gene IDs

3939 (Human); 16828 (Mouse); 24533 (Rat)

Alternate Names

Cell proliferation-inducing gene 19 protein; EC 1.1.1; EC 1.1.1.27; GSD11; Lactate Dehydrogenase A; lactate dehydrogenase M; LDH muscle subunit; LDH1; LDHA; LDH-A; LDHM; LDH-M; L-lactate dehydrogenase A chain; proliferation-inducing gene 19; Renal carcinoma antigen NY-REN-59